Data gathered: May 29
AI Stock Analysis - Lexicon Pharmaceuticals (LXRX)
Analysis generated April 24, 2024. Powered by Chat GPT.
Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of breakthrough treatments for human disease. The company has made significant strides in the development of drugs in diabetes, irritable bowel syndrome, and other areas. Their pipeline includes innovative drug candidates that address unmet medical needs, and the company continues to invest in robust research and development.
Stock Alerts - Lexicon Pharmaceuticals (LXRX)
 |
Lexicon Pharmaceuticals | May 22 Price is up by 7.5% in the last 24h. |
|
Lexicon Pharmaceuticals | May 21 Price is up by 7.7% in the last 24h. |
|
Lexicon Pharmaceuticals | May 14 Price is down by -9.5% in the last 24h. |
|
Lexicon Pharmaceuticals | May 6 Price is down by -7.4% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Lexicon Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 9,000 | Sign up | Sign up | Sign up |
| Employee Rating | 68 | Sign up | Sign up | Sign up |
| Google Trends | 16 | Sign up | Sign up | Sign up |
| Patents | 18 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | N/A | Sign up | Sign up | Sign up |
| Facebook Followers | 969 | Sign up | Sign up | Sign up |
| Reddit Mentions | 3 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 234 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 13,656 | Sign up | Sign up | Sign up |
| Twitter Followers | 594 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 23 | Sign up | Sign up | Sign up |
| Linkedin Employees | 334 | Sign up | Sign up | Sign up |
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products.
| Price | $0.70 |
| Target Price | Sign up |
| Volume | 3,670,000 |
| Market Cap | $251M |
| Year Range | $0.29 - $2.08 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Woodline Partners LP Lowers Stock Holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)May 28 - ETF Daily News |
 |
Contrasting Lexicon Pharmaceuticals (NASDAQ:LXRX) & Grifols (NASDAQ:GRFS)May 25 - ETF Daily News |
|
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Receives $3.67 Consensus Target Price from AnalystsMay 23 - ETF Daily News |
 |
Lexicon Pharmaceuticals, Inc. (LXRX): Analysts See 285% Upside PotentialMay 21 - Yahoo Entertainment |
|
HC Wainwright Issues Positive Estimate for LXRX EarningsMay 17 - ETF Daily News |
|
Stifel Financial Corp Acquires 60,856 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)May 17 - ETF Daily News |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 1.3M | 30,000 | 1.2M | -25M | -26M | -0.070 |
| Q4 '24 | 27M | 350,000 | 26M | -34M | -30M | -0.090 |
| Q3 '24 | 1.8M | 71,000 | 1.7M | -65M | -60M | -0.180 |
| Q2 '24 | 1.6M | 170,000 | 1.5M | -53M | -51M | -0.170 |
| Q1 '24 | 1.1M | 180,000 | 960,000 | -48M | -44M | -0.200 |
Insider Transactions View All
| COATS LONNEL filed to buy 914,359 shares at $1.1. November 17 '23 |
| Amouyal Philippe filed to buy 240,332 shares at $1. November 14 '23 |
| COATS LONNEL filed to buy 824,359 shares at $1. November 13 '23 |
| DEBBANE RAYMOND filed to buy 1,340,847 shares at $1. October 12 '23 |
| DEBBANE RAYMOND filed to buy 1,192,027 shares at $1.1. October 12 '23 |
Similar companies
Read more about Lexicon Pharmaceuticals (LXRX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Lexicon Pharmaceuticals?
The Market Cap of Lexicon Pharmaceuticals is $251M.
What is the current stock price of Lexicon Pharmaceuticals?
Currently, the price of one share of Lexicon Pharmaceuticals stock is $0.70.
How can I analyze the LXRX stock price chart for investment decisions?
The LXRX stock price chart above provides a comprehensive visual representation of Lexicon Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Lexicon Pharmaceuticals shares. Our platform offers an up-to-date LXRX stock price chart, along with technical data analysis and alternative data insights.
Does LXRX offer dividends to its shareholders?
As of our latest update, Lexicon Pharmaceuticals (LXRX) does not offer dividends to its shareholders. Investors interested in Lexicon Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Lexicon Pharmaceuticals?
Some of the similar stocks of Lexicon Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.